Citicoline

Both support brain structure and function

Comprehensive brain health support

⊕ Bacopa Monnieri

stacks-well

Different mechanisms for cognitive enhancement

Enhanced memory and focus from multiple angles

⟡ Alpha-GPC

Different choline sources with complementary effects

Enhanced acetylcholine and membrane support

Top studies from 38+ peer-reviewed papers

📚meta-analysisn=4281

Martí-Carvajal AJ et al. • The Cochrane database of systematic reviews (2020)

“This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with acute ischemic stroke.”

Key Findings:

A pooled analysis of eight trials indicates there may be little or no difference in all-cause mortality comparing citicoline with placebo (17.3% versus 18.5%; RR 0.94, 95% CI 0.83 to 1.07; I² = 0%; low-quality evidence due to risk of bias).
Four trials found no difference in the proportion of patients with disability or dependence in daily activities according to the Rankin scale comparing citicoline with placebo (21.72% versus 19.23%; RR 1.11, 95% CI 0.97 to 1.26; I² = 1%; low-quality evidence due to risk of bias).
Meta-analysis of three trials indicates there may be little or no difference in serious cardiovascular adverse events comparing citicoline with placebo (8.83% versus 7.77%; RR 1.04, 95% CI 0.84 to 1.29; I² = 0%; low-quality evidence due to risk of bias).
Four trials assessing functional recovery with the Barthel Index at a cut-off point of 95 points or more did not find differences comparing citicoline with placebo (32.78% versus 30.70%; RR 1.03, 95% CI 0.94 to 1.13; I² = 24%; low-quality evidence due to risk of bias).

📚meta-analysisn=4039

Shi PY et al. • Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban (2016)

“In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.”

Key Findings:

The overall rate of adverse events in citicoline group was not significantly different from that in control group (P=0.30).
The quality of included articles reached moderate-low level.
In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.

📚meta-analysisn=494

Kruoch Z et al. • The Cochrane database of systematic reviews (2025)

“Neurotrophic keratopathy is a rare condition with an array of etiologies, which poses challenges for research in terms of study design, participant recruitment, and consensus on objective outcome measures.”

Key Findings:

Meta-analysis of two studies showed that rhNGF may slightly improve corneal re-epithelialization (defined as < 0.5 mm of corneal staining) (RR 1.88, 95% CI 1.37 to 2.58; I2 = 0%; 148 participants; low-certainty evidence).
The same two studies assessed complete corneal re-epithelialization (defined as < 0.1 mm of corneal staining) and found similar results but with substantial heterogeneity in the meta-analysis (RR 2.75, 95% CI 1.82 to 4.16; I2 = 72%; 148 participants; low-certainty evidence).
Meta-analysis of two studies showed that rhNGF may not improve visual acuity (RR 0.07, 95% CI -0.58 to 0.71; I2 = 0%; 151 participants; low-certainty evidence).
Meta-analysis of two studies suggested that medical interventions, specifically rb-bFGF, may improve corneal sensitivity (MD 8.43, 95% CI 1.90 to 14.97; I2 = 0%; 60 participants; very low-certainty evidence), but the evidence is very uncertain.

📚meta-analysis

Bonvicini M et al. • Nutrients (2023)

“The overall quality of the studies was poor.”

Key Findings:

Overall, citicoline improved cognitive status, with pooled standardized mean differences ranging from 0.56 (95% CI: 0.37-0.75) to 1.57 (95% CI: 0.77-2.37) in different sensitivity analyses.
Further research warranted to confirm findings

📚systematic-reviewn=5299

Compare with Others Find Based on Your Goals

Dean RL et al. • The Cochrane database of systematic reviews (2021)

“Our findings show that ketamine and esketamine may be more efficacious than placebo at 24 hours.”

Key Findings:

The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).
Ketamine may reduce depression rating scale scores over placebo at 24 hours, but the evidence is very uncertain (standardised mean difference (SMD) -0.87, 95% CI -1.26 to -0.48; n = 231, studies = 8, very low-certainty evidence).
There was no difference in the number of participants assigned to ketamine or placebo who dropped out for any reason (OR 1.25, 95% CI 0.19 to 8.28; n = 201, studies = 6, very low-certainty evidence).
When compared with midazolam, the evidence showed that ketamine increases remission rates at 24 hours (OR 2.21, 95% CI 0.67 to 7.32; n = 122,studies = 2, low-certainty evidence).

View all 38+ studies

What would you like to do next?

Related Supplements

Tc7.5

Theacrine

7.5/10

Purine alkaloid that activates adenosine and dopamine pathways for sustained energy — no tolerance buildup or jitteriness.

Alc9.0

Acetyl-L-Carnitine

Acetylated carnitine that crosses the blood-brain barrier to fuel mitochondrial energy and donate acetyl groups for acetylcholine synthesis.

Caf9.5

Caffeine

9.5/10

Blocks adenosine receptors to boost alertness, reaction time, and endurance — one of the most proven ergogenic aids.

Dha9.0

DHEA

Adrenal hormone precursor that declines with age, supporting hormone balance, energy, and body composition.

Cit8.5

Citicoline

compound

Citicoline (CDP-Choline)

Dual precursor to acetylcholine and phosphatidylcholine — enhances memory, focus, and brain cell membrane repair.

mentalcognitionfocusmemorybrain

38+ studies

Evidence

Reviewed 19 days ago

high

Safety

250-500mg daily

Dose

4-8 weeks

Time to Effect

Cognizin® branded citicoline

Best Form

Mechanisms of Action

⚡

Acetylcholine Synthesis

Provides choline for neurotransmitter production

🔧

Membrane Repair

Supports brain cell membrane structure

🎯

Dopamine Support

May increase dopamine receptor density

Biological PathwayBeta

How Citicoline works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.

Supplement

Molecular Target

Biological Process

Health Outcome

Strong

Moderate

Emerging

strong

moderate

emerging

Tap node to isolate • Pinch to zoom • Tap edge for research

Recommended Dose

250-500mg daily

250mg1000mg

Optimal Timing

Morning for daytime cognitive enhancement

Can be taken without food

Available Forms

Form	Type
💊Cognizin® branded citicoline	Recommended
💊Generic citicoline	Alternative
💊CDP-choline	Alternative

Cognizin is the most-studied branded form. Quality can vary with generic versions.

Duration

Minimum: 4 weeks

Optimal: 8 weeks

Cycling: Not required

Note: Can be taken with or without food. Morning dosing preferred for focus benefits. Some split dose AM/PM.

🎯

Sharper Focus

Better attention and concentration

⏱️ 1-4 weeks

75% of users notice thispositive

📚

Improved Memory

Enhanced learning and recall

⏱️ 4-8 weeks

70% of users notice thispositive

💡

Mental Clarity

Clearer thinking and reduced brain fog

⏱️ 1-2 weeks

65% of users notice thispositive

High SafetyMax safe dose: Up to 2000mg/day used in clinical studies

🟢

Pregnant/nursing

Limited safety data; consult healthcare provider

🟢

Elderly

Well-studied in older adults; may be particularly beneficial

Who Should NOT Take This

None known at recommended doses

Drug Interactions

Anticholinergic drugsmild

May counteract anticholinergic effects

Cholinergic drugsmild

Additive cholinergic effects

Possible Side Effects

Headache

milduncommon

Tip: Reduce dose

Insomnia

mildrare

Tip: Take earlier in day

GI upset

mildrare

Tip: Take with food

Warnings

Very well tolerated
May cause insomnia if taken too late
Effects are subtle but cumulative

⟡ Omega-3

Both support brain structure and function

Comprehensive brain health support

⊕ Bacopa Monnieri

stacks-well

Different mechanisms for cognitive enhancement

Enhanced memory and focus from multiple angles

⟡ Alpha-GPC

Different choline sources with complementary effects

Enhanced acetylcholine and membrane support

Top studies from 38+ peer-reviewed papers

📚meta-analysisn=4281

Martí-Carvajal AJ et al. • The Cochrane database of systematic reviews (2020)

“This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with acute ischemic stroke.”

Key Findings:

A pooled analysis of eight trials indicates there may be little or no difference in all-cause mortality comparing citicoline with placebo (17.3% versus 18.5%; RR 0.94, 95% CI 0.83 to 1.07; I² = 0%; low-quality evidence due to risk of bias).
Four trials found no difference in the proportion of patients with disability or dependence in daily activities according to the Rankin scale comparing citicoline with placebo (21.72% versus 19.23%; RR 1.11, 95% CI 0.97 to 1.26; I² = 1%; low-quality evidence due to risk of bias).
Meta-analysis of three trials indicates there may be little or no difference in serious cardiovascular adverse events comparing citicoline with placebo (8.83% versus 7.77%; RR 1.04, 95% CI 0.84 to 1.29; I² = 0%; low-quality evidence due to risk of bias).
Four trials assessing functional recovery with the Barthel Index at a cut-off point of 95 points or more did not find differences comparing citicoline with placebo (32.78% versus 30.70%; RR 1.03, 95% CI 0.94 to 1.13; I² = 24%; low-quality evidence due to risk of bias).

📚meta-analysisn=4039

“In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.”

Key Findings:

The overall rate of adverse events in citicoline group was not significantly different from that in control group (P=0.30).
The quality of included articles reached moderate-low level.
In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.

📚meta-analysisn=494

Kruoch Z et al. • The Cochrane database of systematic reviews (2025)

“Neurotrophic keratopathy is a rare condition with an array of etiologies, which poses challenges for research in terms of study design, participant recruitment, and consensus on objective outcome measures.”

Key Findings:

Meta-analysis of two studies showed that rhNGF may slightly improve corneal re-epithelialization (defined as < 0.5 mm of corneal staining) (RR 1.88, 95% CI 1.37 to 2.58; I2 = 0%; 148 participants; low-certainty evidence).
The same two studies assessed complete corneal re-epithelialization (defined as < 0.1 mm of corneal staining) and found similar results but with substantial heterogeneity in the meta-analysis (RR 2.75, 95% CI 1.82 to 4.16; I2 = 72%; 148 participants; low-certainty evidence).
Meta-analysis of two studies showed that rhNGF may not improve visual acuity (RR 0.07, 95% CI -0.58 to 0.71; I2 = 0%; 151 participants; low-certainty evidence).
Meta-analysis of two studies suggested that medical interventions, specifically rb-bFGF, may improve corneal sensitivity (MD 8.43, 95% CI 1.90 to 14.97; I2 = 0%; 60 participants; very low-certainty evidence), but the evidence is very uncertain.

📚meta-analysis

Bonvicini M et al. • Nutrients (2023)

“The overall quality of the studies was poor.”

Key Findings:

Overall, citicoline improved cognitive status, with pooled standardized mean differences ranging from 0.56 (95% CI: 0.37-0.75) to 1.57 (95% CI: 0.77-2.37) in different sensitivity analyses.
Further research warranted to confirm findings

📚systematic-reviewn=5299

Compare with Others Find Based on Your Goals

Dean RL et al. • The Cochrane database of systematic reviews (2021)

“Our findings show that ketamine and esketamine may be more efficacious than placebo at 24 hours.”

Key Findings:

The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).
Ketamine may reduce depression rating scale scores over placebo at 24 hours, but the evidence is very uncertain (standardised mean difference (SMD) -0.87, 95% CI -1.26 to -0.48; n = 231, studies = 8, very low-certainty evidence).
There was no difference in the number of participants assigned to ketamine or placebo who dropped out for any reason (OR 1.25, 95% CI 0.19 to 8.28; n = 201, studies = 6, very low-certainty evidence).
When compared with midazolam, the evidence showed that ketamine increases remission rates at 24 hours (OR 2.21, 95% CI 0.67 to 7.32; n = 122,studies = 2, low-certainty evidence).

View all 38+ studies

What would you like to do next?

Related Supplements

Tc7.5

Theacrine

7.5/10

Purine alkaloid that activates adenosine and dopamine pathways for sustained energy — no tolerance buildup or jitteriness.

Alc9.0

Acetyl-L-Carnitine

Acetylated carnitine that crosses the blood-brain barrier to fuel mitochondrial energy and donate acetyl groups for acetylcholine synthesis.

Caf9.5

Caffeine

9.5/10

Blocks adenosine receptors to boost alertness, reaction time, and endurance — one of the most proven ergogenic aids.

Dha9.0

DHEA